Investigational drug · Phase 2
TRI-611
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for ALK-positive NSCLC, ALK-Positive Lung Cancer, ALK-positive Non-small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "TRI-611"
First trial start
2026
Mar 11, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TRI-611", any sponsor or status.
Conditions studied
As listed on its trial records.
- ALK-positive NSCLC
- ALK-Positive Lung Cancer
- ALK-positive Non-small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "TRI-611" as an intervention, largest first.
TRIANA Biomedicines, Inc.Industry
NCT07491497 · 160 participants (planned) · Start Mar 11, 2026 · Primary completion May 31, 2029
Drug: TRI-611 · For: ALK-positive NSCLC; ALK-Positive Lung Cancer; ALK-positive Non-small Cell Lung Cancer
Sites: San Francisco, California; Aurora, Colorado; Boston, Massachusetts · 20 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- TRI-611, a selective, brain-penetrant molecular glue degrader of ALK.
Conery AR, La DS, Alekseyenko AA, et al. · Nature 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.